Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2007

Open Access 01-12-2007 | Research Article

Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands

Authors: Fernie J. A. Penning-van Beest, Jeroen Koerselman, Ron M. C. Herings

Published in: International Journal of Clinical Pharmacy | Issue 6/2007

Login to get access

Abstract

Objective

Coumarin anticoagulants are prone to potentially life-threatening drug-drug interactions due to a combination of unfavorable properties. However, real life data on the actual occurrence are scarce. The aim of this study was to quantify and qualify potential drug interactions with coumarin anticoagulants in daily practice.

Methods

A cohort study including all users of phenprocoumon or acenocoumarol during the period 1991–2003 in the PHARMO Record Linkage System. All 24 individual drugs and 11 drug groups interacting with coumarins according to central database used in the Dutch pharmacies were considered.

Main outcome measure

Frequency and type of potential drug interactions during anticoagulant therapy with coumarins.

Results

48,627 out of 76,455 mainly acenocoumarol-users (64%) were dispensed at least one potentially interacting drug (PID) during anticoagulant therapy. About 35% of these cases were dispensed a (very) strongly interacting drug, whereas 3% were dispensed a contraindicated drug. Antibacterial drugs and NSAIDs (39% and 37% of all users, respectively) were the most frequently dispensed PIDs.

Conclusion

Potential drug interactions with coumarins frequently occur in daily practice, confronting two-thirds of patients with an increased risk of bleeding. To a large part, this is attributable to commonly prescribed medication like antibacterial drugs and NSAIDs. This situation substantiates the need for proper monitoring or new anticoagulants with less drug–drug interactions.
Literature
1.
go back to reference British Committee for Standards in Haemotology. Guidelines on oral anticoagulation. 3rd ed. Br J Haematol 1998;101(2):374–87. British Committee for Standards in Haemotology. Guidelines on oral anticoagulation. 3rd ed. Br J Haematol 1998;101(2):374–87.
2.
go back to reference Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1 Suppl):8S–21S.PubMedCrossRef Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1 Suppl):8S–21S.PubMedCrossRef
3.
go back to reference Sadowski JA, Booth SL, Mann KG, Malhotra OP, Bovill EG. Structure and mechanism of activation of vitamin K antagonists. London: Arnold; 1996. Sadowski JA, Booth SL, Mann KG, Malhotra OP, Bovill EG. Structure and mechanism of activation of vitamin K antagonists. London: Arnold; 1996.
4.
go back to reference Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996;30(6):416–44.PubMedCrossRef Harder S, Thurmann P. Clinically important drug interactions with anticoagulants. An update. Clin Pharmacokinet 1996;30(6):416–44.PubMedCrossRef
5.
go back to reference Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165(10):1095–106.PubMedCrossRef Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165(10):1095–106.PubMedCrossRef
6.
go back to reference Herings RMC. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in The Netherlands. Thesis. Utrecht: Utrecht University; 1993. Herings RMC. PHARMO: a record linkage system for postmarketing surveillance of prescription drugs in The Netherlands. Thesis. Utrecht: Utrecht University; 1993.
7.
go back to reference Catalan VS, Lelorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3(6):417–26.PubMedCrossRef Catalan VS, Lelorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3(6):417–26.PubMedCrossRef
8.
go back to reference Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 2004;24(12):1668–74.PubMedCrossRef Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 2004;24(12):1668–74.PubMedCrossRef
9.
go back to reference Howard PA, Ellerbeck EF, Engelman KK, Patterson KL. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2002;11(7):569–76.PubMedCrossRef Howard PA, Ellerbeck EF, Engelman KK, Patterson KL. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2002;11(7):569–76.PubMedCrossRef
10.
go back to reference Ufer M. Comparative pharmacokinetics of vitamin k antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005;44(12):1227–46.PubMedCrossRef Ufer M. Comparative pharmacokinetics of vitamin k antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005;44(12):1227–46.PubMedCrossRef
11.
go back to reference Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 1996;348(9025):423–8.PubMedCrossRef Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 1996;348(9025):423–8.PubMedCrossRef
12.
go back to reference van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996;76(1):12–6.PubMed van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996;76(1):12–6.PubMed
13.
go back to reference Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95(3):315–28.PubMedCrossRef Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993;95(3):315–28.PubMedCrossRef
14.
go back to reference Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119(1 Suppl):108S–121S.PubMedCrossRef Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001;119(1 Suppl):108S–121S.PubMedCrossRef
15.
go back to reference Stockley IH. Drug interactions. 6th ed. London: The Pharmaceutical Press; 2002. Stockley IH. Drug interactions. 6th ed. London: The Pharmaceutical Press; 2002.
16.
go back to reference Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002;88(5):705–10.PubMed Visser LE, Penning-van Beest FJ, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, et al. Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002;88(5):705–10.PubMed
17.
go back to reference Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R. Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol 2005;61(5–6):439–44.PubMedCrossRef Penning-van Beest F, Erkens J, Petersen KU, Koelz HR, Herings R. Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol 2005;61(5–6):439–44.PubMedCrossRef
18.
go back to reference Majerus PW, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Goodman Gilman A, Limbird LE editors. The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001. Majerus PW, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Goodman Gilman A, Limbird LE editors. The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001.
Metadata
Title
Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands
Authors
Fernie J. A. Penning-van Beest
Jeroen Koerselman
Ron M. C. Herings
Publication date
01-12-2007
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2007
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-007-9127-x

Other articles of this Issue 6/2007

International Journal of Clinical Pharmacy 6/2007 Go to the issue